美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

The Health Care Select Sector SPDR Premium Income Fund

26.13

-0.0448-0.17%

成交量：1.32萬

成交額：34.53萬

市值：2,665.27萬

市盈率：- -

高：26.17

開：26.17

低：26.07

收：26.17

52周最高：27.35

52周最低：24.20

股本：102.00萬

流通股本：102.00萬

量比：0.20

換手率：1.30%

股息：3.27

股息率：12.50%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

諾和諾德(NVO.US)減肥藥拓展低齡市場：STEP Young試驗顯示司美格魯肽顯著降低兒童肥胖率

諾和諾德(NVO.US)減肥藥拓展低齡市場：STEP Young試驗顯示司美格魯肽顯著降低兒童肥胖率

2026年國家醫保談判在北京啓動；珍視明回應滴眼液抽檢不合格事件 | 醫藥早參

每日经济新闻

「很緊張，汗都出來了！」直擊2025年國家醫保談判首日：中藥企業打頭陣

2026年國家醫保談判開啓！早8點代表入場，多家中藥企業亮相

Hims & Hers在澳大利亞推出GLP-1減肥藥及治療方案

不止步於「減肥藥之王」禮來(LLY.US)擬最高28.8億美元收購Merida加碼自身免疫賽道

不止步於「減肥藥之王」禮來(LLY.US)擬最高28.8億美元收購Merida加碼自身免疫賽道

藥聞 | 英硅智能上市後首份半年報扭虧創新藥研發加速擁抱AI

聯環藥業上半年扭虧為盈集採續採與創新藥研發協同推進

印度糖尿病全球第二多，月費降至14美元，GLP-1減肥藥為何仍賣不動？

华尔街见闻

博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑

中國減肥藥研發公司德睿智藥稱AI助力研發時間縮短一半

惠譽評級：美國醫療保健網絡風險日益增加。

減肥藥營銷「戰事」升級：從名人「代言」到老闆下場，藥企在焦慮什麼？

中國銀河證券：實驗動物為創新藥研發剛需小鼠+猴雙主線高景氣

百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

30周狂賣500萬張！GLP-1引爆行情，減肥藥口服時代來臨

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/XLVI/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"XLVI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLVI\",,,,,undefined,":{"symbol":"XLVI","market":"US","secType":"STK","nameCN":"The Health Care Select Sector SPDR Premium Income Fund","latestPrice":26.1301,"timestamp":1789756414206,"preClose":26.1749,"halted":0,"volume":13209,"delay":0,"changeRate":-0.0017115633679594638,"floatShares":1020000,"shares":1020000,"eps":0,"marketStatus":"交易中","change":-0.0448,"latestTime":"09-18 14:47:39 EDT","open":26.1696,"high":26.17,"low":26.0709,"amount":345252.720792,"amplitude":0.003786,"askPrice":26.5,"askSize":700,"bidPrice":25.67,"bidSize":700,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789761600000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":26.1749,"sharesOutstanding":490000,"nav":26.049558,"aum":26570548.93,"dividendRate":0.125027,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":26.155,"preClose":26.1749,"latestTime":"19:30 EDT","volume":32,"amount":837.6339,"timestamp":1789687804250,"change":-0.0199,"changeRate":-0.00076,"amplitude":0},"volumeRatio":0.197369},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLVI\",,,,,undefined,":{"symbol":"XLVI","floatShares":1020000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.197369,"shares":1020000,"dividePrice":3.266961,"high":26.17,"amplitude":0.003786,"preClose":26.1749,"low":26.0709,"week52Low":24.2,"pbRate":"--","week52High":27.35,"institutionHeld":0,"latestPrice":26.1301,"eps":0,"divideRate":0.125027,"volume":13209,"delay":0,"ttmEps":0,"open":26.1696,"prevYearClose":26.4307,"prevWeekClose":25.71,"prevMonthClose":26.92,"prevQuarterClose":26.3599,"fiveDayClose":25.71,"twentyDayClose":26.9965,"sixtyDayClose":25.8202},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XLVI\",params:#limit:5,,,undefined,":[{"date":"2026-09-01","symbol":"XLVI","amount":0.284682,"announcedDate":"2026-08-31","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-01","defaultRemindTime":1788269400000,"name":"The Health Care Select Sector SPDR Premium Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-03","payableDate":"2026-09-01","currency":"USD","dateTimestamp":1788235200000,"payDate":"2026-09-03"},{"date":"2026-08-03","symbol":"XLVI","amount":0.220362,"announcedDate":"2026-07-31","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"The Health Care Select Sector SPDR Premium Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-05","payableDate":"2026-08-03","currency":"USD","dateTimestamp":1785729600000,"payDate":"2026-08-05"},{"date":"2026-07-01","symbol":"XLVI","amount":0.265104,"announcedDate":"2026-06-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-01","defaultRemindTime":1782912600000,"name":"The Health Care Select Sector SPDR Premium Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-06","payableDate":"2026-07-01","currency":"USD","dateTimestamp":1782878400000,"payDate":"2026-07-06"},{"date":"2026-06-01","symbol":"XLVI","amount":0.20398,"announcedDate":"2026-05-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-01","defaultRemindTime":1780320600000,"name":"The Health Care Select Sector SPDR Premium Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-03","payableDate":"2026-06-01","currency":"USD","dateTimestamp":1780286400000,"payDate":"2026-06-03"},{"date":"2026-05-01","symbol":"XLVI","amount":0.266919,"announcedDate":"2026-04-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"The Health Care Select Sector SPDR Premium Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-05","payableDate":"2026-05-01","currency":"USD","dateTimestamp":1777608000000,"payDate":"2026-05-05"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XLVI\",market:\"US\",,,undefined,":[{"executeDate":"2025-09-02","recordDate":"2025-09-02","paymentDate":"2025-09-05","value":0.373503,"currency":"USD"},{"executeDate":"2025-10-01","recordDate":"2025-10-01","paymentDate":"2025-10-03","value":0.293409,"currency":"USD"},{"executeDate":"2025-11-03","recordDate":"2025-11-03","paymentDate":"2025-11-05","value":0.244969,"currency":"USD"},{"executeDate":"2025-12-01","recordDate":"2025-12-01","paymentDate":"2025-12-03","value":0.273076,"currency":"USD"},{"executeDate":"2025-12-29","recordDate":"2025-12-29","paymentDate":"2025-12-31","value":0.329285,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XLVI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XLVI\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665311633","title":"諾和諾德(NVO.US)減肥藥拓展低齡市場：STEP Young試驗顯示司美格魯肽顯著降低兒童肥胖率","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311633","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665311633?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 20:15","pubTimestamp":1788783311,"startTime":"0","endTime":"0","summary":"诺和诺德在声明中指出，这项名为STEP Young的试验所纳入的全部受试者，在整个研究期间均接受了生活方式干预，包括限制热量摄入和增加体育锻炼。诺和诺德首席科学官马丁·霍尔斯特·兰格表示：“STEP Young试验的积极结果令人振奋，我们看好司美格鲁肽在帮助罹患肥胖的儿童方面的潜力——这些儿童除生活方式调整外，尚需药物治疗以更有效地管理其肥胖状况。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FXH","NVOH","BGIA","NVOX","PINK","THNR","RSPH","XLVI","CURE","IYH","TRUH","NBDS","MEDI","NVOC","PJP","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665311616","title":"諾和諾德(NVO.US)減肥藥拓展低齡市場：STEP Young試驗顯示司美格魯肽顯著降低兒童肥胖率","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311616","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665311616?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 20:15","pubTimestamp":1788783311,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDI","PINK","CURE","NVOX","NVOC","TRUH","XLVI","NBDS","RSPH","FHLC","THNR","PJP","NVOH","BGIA","FXH","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665367071","title":"2026年國家醫保談判在北京啓動；珍視明回應滴眼液抽檢不合格事件 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2665367071","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665367071?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 07:01","pubTimestamp":1788735712,"startTime":"0","endTime":"0","summary":"丨2026年9月7日星期一丨NO.12026年国家医保谈判在北京启动9月5日，2026年国家医保目录谈判竞价和商保创新药目录价格协商在北京启动，预计持续4至5天。新版目录有望于11月底前公布，2027年1月1日起执行。与往年相比，今年国谈整体提前约一个月，已有59个创新药完成参考药预沟通，并新增创新药“预申报”。点评：预沟通与预申报缩短创新药准入周期，有利于药企加快商业化节奏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866183218.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866183218.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","PBPH","BMED","APXH","BK1161","BK1515","XLVI","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665636842","title":"「很緊張，汗都出來了！」直擊2025年國家醫保談判首日：中藥企業打頭陣","url":"https://stock-news.laohu8.com/highlight/detail?id=2665636842","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665636842?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 16:59","pubTimestamp":1788598790,"startTime":"0","endTime":"0","summary":"9月5日早上8时，2026年国家基本医保药品目录谈判竞价及商保创新药目录价格协商工作在北京市西城区全国人大会议中心启动，时代周报记者前往现场了解情况。谈判开始之前，已有数十名药企代表在全国人大会议中心门口等候。8时左右，国家医保局工作人员在会议中心门口点名药企代表进入，8:08左右所有参加上午场谈判的药企代表完成入场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053866015465.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053866015465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BMED","XLVI","APXH","PBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665712357","title":"2026年國家醫保談判開啓！早8點代表入場，多家中藥企業亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=2665712357","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665712357?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 09:47","pubTimestamp":1788572828,"startTime":"0","endTime":"0","summary":"本文来源：时代周报2026年国家基本医保药品目录谈判竞价及商保创新药目录价格协商工作，于9月5日早8点在北京市西城区全国人大会议中心启动。时代周报记者从现场了解到，早8点左右，国家医保局工作人员开始在会议中心门口点名药企代表进入；8:08左右所有参加上午场谈判的药企代表完成入场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053865981910.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053865981910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XLVI","PBPH","BMED","APXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882140","title":"Hims & Hers在澳大利亞推出GLP-1減肥藥及治療方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882140","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664882140?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 10:10","pubTimestamp":1788228656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["JDOC","IYH","PJP","ELIS","FHLC","ELIL","NVOH","LLII","NBDS","FXH","NVOC","CURE","TRUH","XLVI","LLYX","OZEM","PINK","NVOX","MEDI","RSPH","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006809","title":"不止步於「減肥藥之王」 禮來(LLY.US)擬最高28.8億美元收購Merida加碼自身免疫賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006809","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663006809?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 21:12","pubTimestamp":1788181963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼来计划以高达28.8亿美元的现金收购Merida Biosciences Inc.，加码自身免疫与过敏疾病领域，以摆脱对减重和糖尿病两大支柱业务的过度依赖——正是这两大市场助其登顶全球药企市值之巅。今年以来，礼来掀起并购狂潮，迄今已宣布的交易总额超过200亿美元。5月，礼来还达成协议，以最高38亿美元收购三家疫苗研发企业。截至发稿，礼来盘前跌0.2%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FXH","NVOC","PJP","NVOH","PINK","CURE","MEDI","RSPH","IYH","NVOX","TRUH","THNR","NBDS","XLVI","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006800","title":"不止步於「減肥藥之王」 禮來(LLY.US)擬最高28.8億美元收購Merida加碼自身免疫賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006800","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663006800?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 21:12","pubTimestamp":1788181963,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDI","NBDS","PJP","THNR","NVOX","RSPH","XLVI","CURE","NVOH","IYH","TRUH","FXH","PINK","NVOC","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"藥聞 | 英硅智能上市後首份半年報扭虧 創新藥研發加速擁抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663282078?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AGIX","GSKH","IPOS","APXH","BIOY","XLVI","AIPO","LFSC","CHAT","BBP","BK4585","VTHR","BK4588","SBIO","IBB","WRND","ARTY","QTOC","GDOC","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"聯環藥業上半年扭虧為盈 集採續採與創新藥研發協同推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044177?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","GSKH","PBE","SBIO","APXH","WRND","BK0239","IBB","BIOY","LFSC","600513","BK4588","GDOC","XLVI","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663168590","title":"印度糖尿病全球第二多，月費降至14美元，GLP-1減肥藥為何仍賣不動？","url":"https://stock-news.laohu8.com/highlight/detail?id=2663168590","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663168590?lang=zh_tw&edition=fundamental","pubTime":"2026-08-29 05:55","pubTimestamp":1787954138,"startTime":"0","endTime":"0","summary":"印度减肥药市场正在给全球制药行业上一堂关于市场预期的警示课。尽管GLP-1类药物在印度已实现大规模仿制、价格降至每月14美元，销售表现却远逊于预期，揭示出价格之外更深层的文化、社会与监管障碍。截至今年7月，约三十余种仿制GLP-1药物已在印度药房上市。市场冷淡直接冲击了制药行业对印度的增长押注。印度市场本被视为GLP-1药物向美欧以外拓展的重要试验场。","market":"nz","thumbnail":"https://static.tigerbbs.com/62df7fa563e423b513600a842a6669e3","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/62df7fa563e423b513600a842a6669e3"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3780608","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FHLC","MEDI","ELIL","FXH","LLII","JDOC","PJP","OZEM","NVOH","ELIS","THNR","NVOC","NBDS","UUP","UDN","PINK","CURE","IYH","LLYX","XLVI","RSPH","TRUH","MNDmain","NVOX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2662752987","title":"博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752987","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752987?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:57","pubTimestamp":1787813849,"startTime":"0","endTime":"0","summary":"然而，需警惕新药研发政策变化、项目执行延期及市场竞争加剧带来的风险，同时关注经营现金流与净利润背离的情况。后续需重点关注公司在手订单转化进度、临床前及临床研究服务的毛利率变化趋势，以及经营现金流的改善情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787797151251328663","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4585","LFSC","GSKH","BBP","XLVI","300404","BK4588","SPHQ","BK0216","IBB","GDOC","PBE","SBIO","WRND","APXH","BIOY","159399"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662376416","title":"中國減肥藥研發公司德睿智藥稱AI助力研發時間縮短一半","url":"https://stock-news.laohu8.com/highlight/detail?id=2662376416","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662376416?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 12:03","pubTimestamp":1787717002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDI","FXH","NVOC","TRUH","THNR","NVOX","RSPH","PINK","PJP","CURE","CHAT","XLVI","ARTY","NBDS","QTOC","AIPO","IYH","NVOH","VTHR","AGIX","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660649212","title":"惠譽評級：美國醫療保健網絡風險日益增加。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660649212","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660649212?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 04:43","pubTimestamp":1787085794,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XLVI","PINK","BK4588","JHMH","CURE","IYH","RSPH","MOAT","PTH","HYLG","BK4585","FXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490484","title":"減肥藥營銷「戰事」升級：從名人「代言」到老闆下場，藥企在焦慮什麼？","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490484","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660490484?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 18:59","pubTimestamp":1786964340,"startTime":"0","endTime":"0","summary":"2026年以来，国内减肥药赛道的宣发动作愈发密集且新颖。8月16日，一场银屑病慢病管理公益计划在上海启动，活动聚焦于银屑病与肥胖的关系。背后的支持方是信达生物（1801.HK），该公司拥有已经获批的银屑病创新药匹康奇拜单抗，也手握国内明星GLP-1药物玛仕度肽。将其他疾病与肥胖话题关联起来，此次活动侧面打开了减肥药宣传的新思路。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843343562.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843343562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IYH","NBDS","XLVI","PJP","MEDI","CURE","RSPH","FHLC","PINK","TRUH","FXH","NVOC","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中國銀河證券：實驗動物為創新藥研發剛需 小鼠+猴雙主線高景氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BIOY","APXH","BK4585","BK1147","LFSC","BK0276","161027","BBP","WRND","BK1564","GSKH","BK0188","06881","IBB","601881","XLVI","GDOC","PBE","BK4588","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務 不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["APXH","XLVI","BK4585","BBP","BIOY","BK0216","BK0102","GDOC","600721","IBB","PBE","WRND","SBIO","BK4588","LFSC","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LFSC","PBE","BK4588","BBP","BK4585","IBB","WRND","APXH","SBIO","XLVI","BIOY","GDOC","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658667990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","IBB","LFSC","GSKH","600721","BK4588","PBE","XLVI","APXH","GDOC","BK0102","SBIO","BK0216","BBP","BIOY","WRND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658996687","title":"30周狂賣500萬張！GLP-1引爆行情，減肥藥口服時代來臨","url":"https://stock-news.laohu8.com/highlight/detail?id=2658996687","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658996687?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 17:20","pubTimestamp":1786440001,"startTime":"0","endTime":"0","summary":"据开源证券研报，Wegovy口服片剂上市后处方量快速攀升，30周累计突破500万张，有效扩宽了GLP-1药物可及性边界，驱动减重产业链持续高景气。2026年被业内视作GLP-1减肥药的“口服元年”。产业链全面受益随着海外商业化落地持续超预期，全球GLP-1减重市场规模迎来指数级增长。口服GLP-1药物放量带动规模化生产需求激增，海外药企产能逐步承压，持续将生产环节外包至国内优质代工企业。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/11/20260811783677.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/11/20260811783677.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260811/32331742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4590","FXH","NVOC","PJP","BK4144","PINK","CURE","MEDI","GLP","RSPH","IYH","JDOC","TRUH","THNR","NBDS","XLVI","FHLC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}